DePuy Synthes Signs Definitive Agreement to Acquire Assets of JointPoint, Inc. to Enhance Surgical Accuracy and Reproducibility in Hip Replacement

Warsaw, IN, September 3, 2019 – Johnson & Johnson Medical Devices Companies* today announced that DePuy Synthes Products, Inc. has signed a definitive agreement with JointPoint, Inc. to acquire its surgeon-friendly navigation software designed to improve surgical outcomes in hip replacement. The transaction, expected to close this year, is subject to customary closing conditions. Financial terms of the acquisition are not being disclosed.

JointPoint Navigation Software provides surgeons performing hip replacements with a precise analysis of implant selection and positioning through easy-to-use non-invasive computer navigation, pre-surgical digital templating and case planning.  This in turn may lead to more reproducible clinical outcomes. An important feature of the JointPoint software is OneTrial®, which is used to optimize implant combinations based on pre-surgical goals with just two images, and reduce OR time by limiting retrialing.

“JointPoint ties into our strategy to transform hip replacement and is specifically designed for use with the Anterior Approach, a tissue-sparing surgical technique which surgeons are increasingly utilizing and where we have long had an industry-leading presence,” said Aaron Villaruz, Vice President and Global Platform Leader, Hips, DePuy Synthes.

Since July 2017, DePuy Synthes has had an exclusive co-marketing agreement to market the JointPoint platform in the US. Upon close of the transaction, the JointPoint platform will become a DePuy Synthes owned component of an Anterior Approach solution called the ANTERIOR ADVANTAGE which brings together DePuy Synthes implants and instrumentation, exclusive innovative technologies to optimize the surgical experience for the patient, and a world-class professional education program designed to decrease the learning curve and increase surgical reproducibility.

Among the components of the ANTERIOR ADVANTAGE is the KINCISE Surgical Automated System which automates and improves the precision of key steps during hip replacement surgery and is compatible with the JointPoint platform.  Another component of ANTERIOR ADVANTAGE is the ACTIS Total Hip System. Both the KINCISE System and ACTIS System can also be used in traditional posterior approaches to hip replacement. 

DePuy Synthes plans to continue to develop and broaden the JointPoint platform for additional orthopaedic surgery procedures.

About Johnson & Johnson Medical Devices Companies

At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.

About DePuy Synthes

DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding JointPoint. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Neither DePuy Synthes, the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

*The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.

The third-party trademarks used herein are the trademarks of their respective owners.

CONTACT: Monika Schoenbeck  
(312) 221-7410

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button